Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue increased due to strong prime contracts in the DX & SI business and strong analysis and medical claims review services in the Medical Big Data business. Operating profit declined due to lower sales in the Package business, growth investments, efforts to strengthen the structure for expanding new businesses, and temporary cost increases associated with the relocation of the Tokyo headquarters.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥15,337 million (YoY +2.7%) |
| Operating profit | ¥1,282 million (YoY -24.3%) |
| Ordinary income | ¥1,358 million (YoY -21.0%) |
| Profit attributable to owners of the parent | ¥745 million (YoY -32.6%) |
| Net income per share | ¥30.26 |
| Equity ratio | End of the current fiscal period 67.8 / End of previous period 66.2 |
| Total assets | ¥23,648 million |
| Net assets | ¥16,108 million |
| Cash flows from operating activities | ¥2,219,011 thousand |
| Cash flows from investing activities | ¥-782,647 thousand |
| Cash flows from financing activities | ¥-1,607,344 thousand |
| Cash and cash equivalents at end of period | ¥8,647,843 thousand |
| Full-year earnings forecast | Net Sales ¥34,300 million (YoY +5.7%) / Operating profit ¥4,150 million (YoY +6.1%) / Ordinary income ¥4,200 million (YoY +4.5%) / Profit attributable to owners of the parent ¥2,950 million (YoY +12.5%) |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | 45 Yen → 50 Yen（+11.1%） |
| Segment revenue | DX & SI business ¥9,788,354 thousand (YoY +3.7%), Packaging Business ¥3,204,450 thousand (YoY -2.9%), Healthcare Big Data Business ¥1,410,635 thousand (YoY +13.0%), Global Business ¥933,987 thousand (YoY -0.9%) |
| Segment profit | DX & SI business ¥1,737,484 thousand (YoY +4.3%), Packaging Business ¥857,526 thousand (YoY -23.5%), Healthcare Big Data Business ¥147,776 thousand (YoY -23.9%), Global Business ¥-109,223 thousand |
| Depreciation and amortization | ¥115,296 thousand |
| Impairment loss | ¥155,798 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Impairment loss ¥155,798 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors, individual investors and analysts) |
| Issued Shares at Period-End | 24,836,920 |
| Treasury Shares at Period-End | 436,819 |
| Factors Behind Changes in Business Performance | Revenue increased due to strong prime contracts in the DX & SI business and strong analysis and medical claims review services in the Medical Big Data business. Operating profit declined due to lower sales in the Package business, growth investments, efforts to strengthen the structure for expanding new businesses, and temporary cost increases associated with the relocation of the Tokyo headquarters. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The DX & SI business performed steadily, driven mainly by prime contracts for telecommunications, financial and securities, and insurance companies. The Package business reported lower revenue from sales of the “GAKUEN” series and EUC development, while profit declined due to growth investments and efforts to establish a consulting structure. In the Medical Big Data business, analysis services and medical claims review services performed well, but profit declined due to efforts to strengthen the structure for growth investments and the expansion of new businesses. Company-wide, temporary cost increases were incurred in connection with the relocation of the Tokyo headquarters.